Challenges in Pediatric drug development

Pediatric drug development is a challenge for over the past half a century. There are quite a few childhood diseases which have significant occurrence rates in pediatric subjects but  for which there are no approved drugs. Reports say that as a result of low prioritization of pediatric drug development globally about 75% of drugs do not carry regulatory approval for use in infants or children; ~66% of medications used in children in the US are used off label, 50% in Europe and in Japan it is less than 20%. Most medications in these regions donot contain package inserts have adequate information for treating infants or children. This session will address all such issues including R&D, F&D and regulatory framework with research scientists from different pharmaceutical industries and also drug discovery researchers.

  • Regulatory framework
  • Challenges in developing and prescribing drugs for children
  • Models for enhancing pediatric drug development
  • Challenges and opportunities for the future
  • Differences in Drug response
  • Differences in Toxicity profiles
  • Differences in Drug metabolism
  • Route of administration
  • Dosage form suitability
  • Patient compliance

Related Conference of Challenges in Pediatric drug development

June 22-23, 2026

35th World Congress on Clinical Pediatrics

Barcelona, Spain
June 29-30, 2026

6th Global Summit on Pediatric Nursing

Barcelona, Spain
July 27-28, 2026

3rd World Pediatric Conference

London, UK
August 18-19, 2026

8th World Pediatric Infectious Disease Congress

Paris, France
September 07-08, 2026

24rd World Congress on Clinical Pediatrics

Toronto, Canada
September 14-15, 2026

26th Annual Congress on Pediatrics & Neonatology

Rome, Italy
November 19-20, 2026

37th European Pediatrics Conference

Dubai, UAE

Challenges in Pediatric drug development Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in